Latest
Research, clinical trials, regulatory updates, and industry analysis from the longevity medicine world.
This week's radar covers blood-based Alzheimer's biomarkers, FDA-cleared imaging AI, DXA/DEXA upgrades, wearable VO₂ estimates, and smarter questions for buyers.
A practical 2026 guide to biological age testing in longevity clinics: epigenetic clocks, proteomic and multi-omics clocks, imaging-derived organ age, inflammatory markers, and the clinical tests that actually change decisions.
A clear 2026 guide to what longevity clinics do, what they cost, which tests matter, red flags to avoid, and how to compare clinics safely.
A practical 2026 cost guide for executive health programs, longevity assessments, imaging-heavy diagnostics, memberships, and what buyers should ask before paying.
Longevity clinics are usually regulated through doctors, medicines, devices, diagnostics, premises, and advertising claims — not as one universal clinic category.
Fountain Life is one of the clearest examples of premium diagnostic longevity medicine. Here is what the membership appears to cost, who it fits, and which alternatives to compare.
A practical buyer’s guide to longevity health assessments: biomarkers, imaging, genetics, fitness testing, costs, and the questions to ask before booking.
Spain is becoming one of Europe’s most interesting longevity clinic markets. Here is how Progevita, SHA, RoseBar Ibiza, and other options differ.
Full-body MRI is now common in longevity medicine. The evidence suggests real detection potential, but also substantial incidental findings and false positives.
A practical checklist for choosing a longevity clinic in 2026: diagnostics, physician oversight, evidence quality, follow-up, pricing, and red flags.
A country-by-country decision guide for choosing a longevity clinic in Europe: Swiss prestige, Spain’s value and treatment breadth, German diagnostics, or UK outpatient optimization.
Peptide therapy is the fastest-growing treatment category at longevity clinics. But RFK Jr.'s push to reclassify 12 banned peptides has created confusion. Here's which peptides clinics actually use, what the evidence says, what they cost, and how to choose a clinic.
A UC Berkeley study found that combining oxytocin with an Alk5 inhibitor extended lifespan by 70% in frail elderly male mice. Benefits were sex-specific — females showed no lasting improvement. Here's what the data says and whether it could reach humans.
A March 2026 Nature Aging review by 25+ scientists from the University of Oslo and international collaborators consolidates the evidence for NAD+ in neurodegenerative disease. Here's what the science says — and what it doesn't.
A Europe-specific guide to 23 longevity clinics across 8 countries, with our top picks for luxury, diagnostics, value, and therapeutic fasting based on WLC editorial data.
Cleveland Clinic Florida is hosting public longevity panels with cardiologists and oncologists over cocktails. When hospital systems start marketing prevention to consumers, the longevity industry has arrived.
Eli Lilly signed a $2.75B deal with Insilico Medicine for AI-generated drug candidates targeting age-related diseases. Big Pharma is now investing billions in longevity drug discovery. Here's what it means for clinics and patients.
Clinique La Prairie is opening a 52-room health resort at AMAALA, Saudi Arabia's mega wellness destination. Construction photos are circulating on X. Here's what we know and what it signals for the longevity industry.
Fountain Life is expanding from 4 to 7+ US locations in 2026, with new centers in Houston, Miami, and Los Angeles. Here's what the expansion means for the US longevity market and how their model compares.
Niagen Bioscience is partnering with OneSpaWorld to offer pharmaceutical-grade NAD+ IV therapy at 80+ medi-spa clinics on high-end cruise ships starting summer 2026. Is this democratization or dilution of longevity medicine?
Epigenetic age tests are marketed as the ultimate longevity metric. But the same sample can produce a 15-year discrepancy, there are no clinical standards, and better diagnostics exist. Here's what the science actually says.
Buchinger Wilhelmi's 70-year fasting tradition vs Chenot Palace's ultra-luxury detox on Lake Lucerne. We compare the evidence, treatments, pricing, and who each clinic serves best.
Clinique La Prairie (est. 1931, Montreux) and Palazzo Fiuggi (est. 2021, Lazio) both command ultra-luxury positioning. But they differ fundamentally on clinical depth, heritage, and what you're actually paying for.
Fountain Life and Human Longevity Inc. both offer premium diagnostic assessments in the US, but differ on genomic depth, AI integration, pricing model, and geographic reach. A data-driven comparison.
Lanserhof and SHA Wellness Clinic represent two distinct philosophies of luxury longevity medicine in Europe — Austrian Alpine precision vs. Spanish Mediterranean integration. Here's how they compare on treatments, pricing, and experience.
Mayo Clinic and Cleveland Clinic both offer elite executive health programs with institutional credibility no startup can match. We compare their diagnostics, specialties, pricing, and how they fit into the longevity clinic landscape.
NAD+ therapy is the most-requested treatment at longevity clinics. But should you get an IV infusion or take oral NMN/NR? We break down the science, dosing, costs, and which clinics offer what.
A head-to-head comparison of two leading European residential longevity clinics — Progevita in Valencia and Clinique La Prairie in Montreux — covering philosophy, treatments, pricing, and who each one is best for.
Progevita and Lanserhof both offer residential longevity programs in Europe, but diverge sharply on treatment range, pricing, and philosophy. A data-driven comparison to help you decide.
Both are residential longevity clinics on Spain's Mediterranean coast. But Progevita and SHA Wellness Clinic differ sharply on philosophy, treatment range, pricing, and who they serve. A head-to-head comparison.
Joe Rogan underwent plasmapheresis at Ways2Well in Austin, calling it 'changing the oil in your body.' The FDA-approved procedure is gaining traction in longevity clinics. Here's what it is, the evidence, costs, and whether it's right for you.
Senolytics promised to extend healthspan by clearing senescent cells. But recent clinical trial setbacks have cooled the hype. Here's the real state of the field in 2026: which companies are advancing, what failed, what clinics offer, and what the science actually supports.
We analyzed 55 longevity clinics across 18 countries on diagnostics, treatments, evidence basis, and accessibility. Here's the definitive 2026 ranking — no affiliate deals, no sponsored placements.
With FDA peptide reclassification restoring access to 14 key peptides, longevity clinics offering peptide therapy are seeing renewed interest. Here's what to look for in a peptide clinic, which peptides are commonly offered, and how to evaluate quality and safety.
HHS Secretary Kennedy announced ~14 peptides will move from Category 2 (restricted) to Category 1 (legal for compounding). Here's what the reclassification means for longevity medicine, which peptides are returning, and why physician oversight matters more than ever.
Stem cell therapy for aging jumped from $29.9B (2025) to $31.8B (2026), with allogeneic MSCs dominating. But which clinics offer the best programs? This guide compares top destinations by cell type, protocol, safety, and cost.
Therapeutic plasma exchange (TPE) is having its moment: Joe Rogan tried it, longevity clinics are adding it to their menus, and a Buck Institute trial showed 2.6-year biological age reduction. But what is it, what does the science say, and where can you actually get it?
UT Health San Antonio launches a National Institute on Aging-funded rapamycin trial with 84 older adults—one of the largest longevity-focused clinical studies to date. The shift: from off-label speculation to evidence-based dosing.
Human Longevity Inc. partners with LEV Foundation to study blood from centenarians and supercentenarians using multi-omic analysis — seeking biomarkers that explain why some people age far more slowly.
The LA Times maps how Southern California has become a longevity industry hub — where biotech labs, venture capital, AI diagnostics, and concierge medicine are converging around healthspan extension.
A sector maturity signal: less hype, more real medicine — protocols, traceability, and clinical oversight.
A critical analysis of the 'longevity clinic' phenomenon: serious prevention and offerings with limited evidence coexist. The challenge is separating signal from noise.
The U.S. government's ARPA-H launches the PROSPR program: $144M over five years to identify early aging biomarkers and run the first clinical trials explicitly aimed at extending healthy lifespan.
A clinic announces a longevity program focused on men: coordinated assessment + roadmap + follow-up. A signal of the sector's 'productization.'
BBC examines the longevity industry boom: extreme diagnostics, expensive programs, and the key question — what part is real prevention and what part is marketing?
Cleveland Clinic becomes Official Healthcare Provider of the PGA TOUR through 2032: clinical integration in the Player Performance Center, sports medicine, and athletic longevity.
A sharp critique of 'longevity marketing': the future is measurable prevention, clear boundaries, and fewer interventions without robust evidence.
An Am Law 100 firm launches a group dedicated to longevity/healthspan: a signal that regulation, privacy, and IP are becoming the real battleground.
The Washington Post investigates the longevity medicine boom — from biohacking expos to high-end clinics — finding that commercial fervor has outpaced both scientific evidence and federal regulation.
An inside look at Biograph: 6 hours, 30+ tests, and 1,000+ data points. The clinical question isn't 'what do you measure' — it's what decisions you change with the data.
A comprehensive review of 2025's longevity milestones: AI-driven drug deals, clinic proliferation, biomarker standardization, and the XPRIZE Healthspan competition reaching its final phase.
The EMA publishes its quarterly ATMP report (Jun–Nov 2025): cell, gene, and tissue therapy. A key regulatory signal for clinics offering stem cells or regenerative therapies.
A new franchise concept of 'longevity studios' blends recovery therapies (red light, HBOT, cold plunge) with clinical upsells (biomarkers, NAD, GLP-1, HRT, peptides, IV).
A Cell Stem Cell study shows that correcting lysosomal dysfunction in aged mouse blood stem cells restores their regenerative capacity eightfold. Significant, but not a clinic treatment yet.
Longevity.Technology launches Longevity Clinics World, a directory of 350+ pre-validated clinics globally. The move signals an industry maturing from niche to mainstream.
An editorial in Aging by its Editor-in-Chief reviews the rapid rise of longevity clinics worldwide, highlighting both their potential for data-driven innovation and the serious risks of cost, standardization gaps, and scientific disconnect.
A systematic review in Nature Metabolism concludes that clinical evidence for NAD+ supplementation in humans remains scarce and results are heterogeneous. More research needed.
Forbes identifies longevity clinics and medical tourism as the dominant wellness trend of 2025 — with biological age testing, epigenetic profiling, and destination diagnostics driving a new category.